Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer

NCT04705649 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT04705649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04705649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Completed
Start date
July 14, 2020
Completion date
June 22, 2023
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer